siRNA therapy reduces triglycerides in patients with rare condition
.RESEARCH FEATURE.19 September 2024.
Plozasiran lowered triglyceride amounts through 80% and also decreased the danger of pancreatitis in people with constant chylomicronemia, with or without a genetic prognosis.